Please assess the completion status of the following clinical trial:

Trial Title: Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age at Screening, verified per site standard operating procedure (SOP)~* Able and willing to provide written informed consent to be screened for and take part in the study~* At Screening, able and willing to provide adequate locator information, as defined per site SOP~* Able and willing to communicate in written and spoken English~* HIV-uninfected at Screening per Algorithm in Appendix II~* In general good health, according to the clinical judgment of the Investigator of Record (IoR) or designee~* Willing to abstain from vaginal, oral and anal intercourse (including receptive anal intercourse), even with a condom; masturbation, and other activities that may cause irritation or injury to the penis during study participation~* Willing to abstain from using any genitally-applied preparations (except use of usual cleansing products for genital hygiene) other than the study product during study participation~* Willing to abstain from non-urgent surgical procedures of the penis/GU area for the duration of study participation (e.g. circumcision)~* At Screening and Enrollment, agrees not to participate in other research studies involving drugs, medical devices, or genital products for the duration of study participation (until all follow-up visits are completed)~Exclusion Criteria:~* Participant report of any of the following:~  * Known adverse reaction to any of the study products or components of the study products (ever)~ * Post-exposure prophylaxis (PEP) for HIV exposure within 6 months prior to Enrollment~ * Penile procedures (e.g. biopsy, circumcision) within 42 days or less prior to Enrollment~ * Participation in any other research study involving drugs, medical devices, or genital products within 30 days or less prior to Enrollment~ * Within the three months prior to Enrollment, history of a non-gonococcal urethritis and/or sexually transmitted infection (STI), including outbreak of genital herpes or condylomata~ * For uncircumcised men, the treatment of candidal balanoposthitis/ balanitis within 30 days prior to Enrollment~ * History of recurrent dermatosis (e.g. eczema)~ * Non-therapeutic injection drug use in the 12 months prior to Screening~ * Currently using an immunosuppressant (with the exception of local nongenital use of low potency products e.g. inhaled corticosteroid for asthma)~ * Has any of the following laboratory abnormalities at Screening:~    * Hemoglobin \< 10.0 g/dL~   * Platelet count \< 100,000/mm3~   * White blood cell count \< 2,000 cells/mm3~   * Alanine transaminase (ALT) and/or aspartate aminotransferase (AST) \> 2.5x the site laboratory upper limit of normal (ULN)~   * Serum creatinine \> 1.3x the site laboratory ULN~   * Calculated creatinine clearance less than 80 mL/min by the Cockcroft-Gault formula where creatinine clearance in mL/min = (140-age in years) x (weight in kg) x 0.85/72 x serum creatinine in mg/dL Note: Otherwise eligible participants with any of the above exclusionary laboratory results may be re-tested. If a participant is re-tested and a non exclusionary result is documented within 30 days of providing informed consent for Screening, the participant may be enrolled.~* At Screening or Enrollment, diagnosed with STI or reproductive tract infection (RTI) requiring treatment, per current Centers for Disease Control and Prevention (CDC) guidelines~* At Screening or Enrollment, has a clinically apparent Grade 1 or higher genital exam finding (observed by study staff)~* At Screening or Enrollment, has Grade 1 or higher genital or urinary symptoms~* At Screening or Enrollment, diagnosed with phimosis or hypospadias~* At Screening or Enrollment, penile, scrotal piercing or penile tattoos observed during genital examination~* Has any other condition that, in the opinion of the IoR/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- matched placebo (Type: PLACEBO_COMPARATOR): None
- universal placebo (Type: PLACEBO_COMPARATOR): None
- dapivirine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete